Defining co-related parameters between 'cymetabolic' flare and 'cyclinical', 'cybiochemical', and 'cyosteoblastic' flare and establishing guidelines for assessing response to treatment in cancer

被引：20
作者：
Basu, Sandip [1 ]
Alavi, Abass [1 ]
机构：
[1] Hosp Univ Penn, Div Nucl Med, Philadelphia, PA 19104 USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2007年 / 34卷 / 04期
关键词：
D O I：
10.1007/s00259-006-0264-6
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：441 / 443
页数：3
相关论文
共 19 条
[1]   Differential response of prostate specific antigen to testosterone surge after luteinizing hormone-releasing hormone analogue in prostate cancer and benign prostatic hyperplasia [J].
Agarwal, DK ;
Costello, AJ ;
Peters, J ;
Sikaris, K ;
Crowe, H .
BJU INTERNATIONAL, 2000, 85 (06) :690-695
[2]   Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours? [J].
Basu, Sandip ;
Nair, Narendra .
NUCLEAR MEDICINE COMMUNICATIONS, 2006, 27 (05) :413-416
[3]   FDG-PET in monitoring therapy of breast cancer [J].
Biersack, HJ ;
Bender, H ;
Palmedo, H .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (Suppl 1) :S112-S117
[4]   Is the flare phenomenon clinically significant? [J].
Bubley, GJ .
UROLOGY, 2001, 58 (2A) :5-9
[5]  
COLEMAN RE, 1988, J NUCL MED, V29, P1354
[6]   Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy [J].
Dehdashti, F ;
Flanagan, FL ;
Mortimer, JE ;
Katzenellenbogen, JA ;
Welch, MJ ;
Siegel, BA .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (01) :51-56
[7]  
KAHAN A, 1984, LANCET, V1, P971
[8]   Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer [J].
Koizumi, M ;
Matsumoto, S ;
Takahashi, S ;
Yamashita, T ;
Ogata, E .
CLINICAL NUCLEAR MEDICINE, 1999, 24 (01) :15-20
[9]  
Kostakoglu L, 2004, J NUCL MED, V45, P56
[10]   PREVENTION OF THE TRANSIENT ADVERSE-EFFECTS OF A GONADOTROPIN-RELEASING HORMONE ANALOG (BUSERELIN) IN METASTATIC PROSTATIC-CARCINOMA BY ADMINISTRATION OF AN ANTIANDROGEN (NILUTAMIDE) [J].
KUHN, JM ;
BILLEBAUD, T ;
NAVRATIL, H ;
MOULONGUET, A ;
FIET, J ;
GRISE, P ;
LOUIS, JF ;
COSTA, P ;
HUSSON, JM ;
DAHAN, R ;
BERTAGNA, C ;
EDELSTEIN, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :413-418
12